Vitae Pharma Revenue, Profits - VTAE Quarterly Income Statement

Add to My Stocks
$21 $0 (0%) VTAE stock closing price Oct 25, 2016 (Closing)

VTAE stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Vitae Pharma stock price. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. Like any other income statement, the VTAE income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a QoQ revenue decline of 0 when compared to the same period in the past. The Vitae Pharma profit and loss statement for 2016 Q2 shows a net profit of $-10.41M. Profits for last year was $-10.01M. Apart from this an investor should also check Vitae Pharma assets and Vitae Pharma free cash flow.

View and download details of revenue and profits for Vitae Pharma for latest & last 40 quarters.
show more
Fiscal year is Jan - Dec2016 Q22016 Q12015 Q4
Vitae Pharma Revenues or Net Sales
---
Cost Of Goods Sold (COGS)---
Vitae Pharma Gross Profit
---
Research & Development Expense7.87M7.63M9.62M
Selling General & Admin Expense2.65M2.49M2.28M
Income Before Depreciation Depletion Amortization-10.53M-10.08M-11.8M
Depreciation Depletion Amortization---
Non Operating Income---
Interest Expense---
Vitae Pharma Pretax Income
-10.41M-10M-11.46M
Provision for Income Taxes---
MinorityInterest---
Investment Gains Losses---
Other Income---
Income Before Extraordinaries & Disc Operations-10.41M-10.01M-11.45M
Extraordinary Items & Discontinued Operations---
Vitae Pharma Profit/ Loss (Net Income)
-10.41M-10.01M-11.45M
Average Shares used to compute Diluted EPS28.3M22.54M21.94M
Average Shares used to compute Basic EPS28.83M22.54M21.94M
Income Before Nonrecurring Items-10.41M-10.01M-11.45M
Income from Nonrecurring Items---
Vitae Pharma Earnings Per Share Basic Net
-0.36-0.44-0.52
Vitae Pharma Earnings Per Share Diluted Net
-0.37-0.44-0.52
EPS Diluted Before Nonrecurring Items-0.37-0.44-0.52
Preferred Dividends Acc Pd---
Dividends Common---
Dividend Per Share Common0.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.

Vitae Pharma stock analysis involves checking at least a few of the important things like:

  • Topline: A growing topline, as seen from the Vitae Pharma revenue chart, as isn't the case with Vitae Pharma indicates a sagging business. One needs to compare the QoQ topline or sales growth of VTAE stock with its peers like VEGPF stock and GLYC stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. VTAE stock had a poor bottom line growth.

The income statement is also called the profit and loss statement. Apart from the VTAE income statement, one can check the Vitae Pharma historical stock prices to check how the price has moved with time.

Other Income Statements - Vitae Pharmaceuticals Inc Industry Peers

Biogen Inc income statement, ChemoCentryx income statement, GlycoMimetics income statement, Merck income statement